[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100394882":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":38,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"Group 1 : Status epilepticus",null,[12],"Other: Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)",{"label":14,"type":6,"description":10,"interventionNames":15},"Group 2 : Dysimmune encephalitis",[16],"Other: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)",{"label":18,"type":6,"description":10,"interventionNames":19},"Group 3 : Control patients",[16],[21,25],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)","Collection of biological samples and clinical\u002Fparaclinical data",[14,18],{"type":6,"name":26,"description":23,"armGroupLabels":27,"otherNames":10},"Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)",[9],[29],{"name":30,"affiliation":31,"role":32},"Vincent NAVARRO, Pr","Hôpital Pitié Salpêtrière - Assitance Publique Hôpitaux de Paris","PRINCIPAL_INVESTIGATOR",[34],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","01 42 16 19 40","vincent.navarro@aphp.fr",[39],{"facility":40,"status":41,"city":42,"state":10,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hôpital de la Pitié Salpêtrière","RECRUITING","Paris","75013","France","FR",{"type":47,"coordinates":48},"Point",[49,50],2.3488,48.85341,{"lat":50,"lon":49},[53,54],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},{"name":55,"role":35,"phone":10,"phoneExt":10,"email":56},"Aurélie HANIN, Dr","aurelie.hanin@icm-institute.org",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100394882","study-of-pathophysiology-of-status-epilepticus-and-dysimmune-encephalitis-100394882",false,"NCT04421846","Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis","COLETTE : Study of the Pathophysiology of Status Epilepticus and Dysimmune Encephalitis and Identification of Valuable Biomarkers","COLETTE","Inclusion Criteria:\n\nGroup 1:\n\n* Patients aged 2 years or above, with status epilepticus.\n* Affiliation to a French social security system excluding \"Aide Médicale\" Etat (AME).\n* Patients or relatives have been informed and given free informed and written consent to participate\n* Patients under legal protection (guardianship, curatorship) or not\n\nGroup 2:\n\n* Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.\n* Affiliation to a French social security system excluding \"Aide Médicale\" Etat (AME).\n* Patients or relatives have been informed and given free informed and written consent to participate\n* Patients under legal protection (guardianship, curatorship) or not\n\nGroup 3:\n\n* Patients aged 18 years or above, without status epilepticus and\u002For dysimmune encephalitis.\n* Affiliation to a French social security system excluding \"Aide Médicale\" Etat (AME).\n* Patients or relatives have been informed and given free informed and written consent to participate\n* Patients under legal protection (guardianship, curatorship) or not\n\nExclusion Criteria:\n\nGroup 1:\n\n* Women with known or clinically detected pregnancy.\n* Patient deprived of liberty\n* Patients with known neurodegenerative disease.\n\nGroup 2:\n\n* Women with known or clinically detected pregnancy.\n* Patient deprived of liberty\n* Patients have been already treated by corticoids or IgIV.\n\nGroup 3:\n\n* Women with known or clinically detected pregnancy.\n* Patient deprived of liberty.\n* Patients with status epilepticus.\n* Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke.","ALL","2 Years",{"count":70,"type":71},400,"ESTIMATED","INTERVENTIONAL",[74],"NA","COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune encephalitis as well as in control patients, to better understand the pathophysiology of these severe epileptic disorders.",[77,78],"Status Epilepticus","Dysimmune Encephalopathy",[80,77,81],"Epilepsy","Autoimmunity","2026-05-19",{"date":84,"type":85},"2026-05-22","ACTUAL",{"date":87,"type":85},"2020-11-25",{"date":89,"type":71},"2033-06-01",{"name":5,"class":6},1]